The relevance of gene panels in movement disorders diagnosis

A lab perspective

Chiara Reale, Celeste Panteghini, Miryam Carecchio, Barbara Garavaglia

Research output: Contribution to journalReview article

3 Citations (Scopus)

Abstract

Next-Generation Sequencing (NGS) is a group of new methods that allow sequencing a variable number of known genes (targeted resequencing) or even the whole human genome (whole genome sequencing-WGS) and have contributed to an exponential genetic knowledge growth, especially in rare diseases, in the past few years. Since 2015, in the Molecular Neurogenetics Unit of Neurological Institute “Carlo Besta”, some gene panels have become available to screen all the known genes associated with Movement Disorders (MD) in children and adults as a diagnostic package. Over 221 patients analyzed (part of the Telethon Network of Genetic Biobanks – TNGB), pathogenic variants were found in 25 (11.31%), allowing a definitive genetic diagnosis. Among them, we found mutations in 10/114 patients with dystonia (8.8%); 10/59 patients with Parkinson's disease (16.9%); 1/25 patients with Neurodegeneration with Brain Iron Accumulation (NBIA) (4%) and 4/23 patients with neurotransmitter and biopterin metabolism synthesis defect (17.4%). Our results are in line with those published in literature; targeted resequencing does not replace Sanger sequencing totally, but its usage needs to be discussed with clinicians taking into account both the patient's clinical picture and radiological and neurophysiological data.

Original languageEnglish
Pages (from-to)285-291
Number of pages7
JournalEuropean Journal of Paediatric Neurology
Volume22
Issue number2
DOIs
Publication statusPublished - Mar 1 2018

Fingerprint

Movement Disorders
Genes
Biopterin
Dystonia
Human Genome
Rare Diseases
Neurotransmitter Agents
Parkinson Disease
Genome
Mutation
Growth

Keywords

  • Gene panel
  • Movement disorders
  • Next-generation sequencing
  • Targeted resequencing

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health
  • Clinical Neurology

Cite this

The relevance of gene panels in movement disorders diagnosis : A lab perspective. / Reale, Chiara; Panteghini, Celeste; Carecchio, Miryam; Garavaglia, Barbara.

In: European Journal of Paediatric Neurology, Vol. 22, No. 2, 01.03.2018, p. 285-291.

Research output: Contribution to journalReview article

@article{76ceb3c0047d46d38a7c0fc7d94dbf6c,
title = "The relevance of gene panels in movement disorders diagnosis: A lab perspective",
abstract = "Next-Generation Sequencing (NGS) is a group of new methods that allow sequencing a variable number of known genes (targeted resequencing) or even the whole human genome (whole genome sequencing-WGS) and have contributed to an exponential genetic knowledge growth, especially in rare diseases, in the past few years. Since 2015, in the Molecular Neurogenetics Unit of Neurological Institute “Carlo Besta”, some gene panels have become available to screen all the known genes associated with Movement Disorders (MD) in children and adults as a diagnostic package. Over 221 patients analyzed (part of the Telethon Network of Genetic Biobanks – TNGB), pathogenic variants were found in 25 (11.31{\%}), allowing a definitive genetic diagnosis. Among them, we found mutations in 10/114 patients with dystonia (8.8{\%}); 10/59 patients with Parkinson's disease (16.9{\%}); 1/25 patients with Neurodegeneration with Brain Iron Accumulation (NBIA) (4{\%}) and 4/23 patients with neurotransmitter and biopterin metabolism synthesis defect (17.4{\%}). Our results are in line with those published in literature; targeted resequencing does not replace Sanger sequencing totally, but its usage needs to be discussed with clinicians taking into account both the patient's clinical picture and radiological and neurophysiological data.",
keywords = "Gene panel, Movement disorders, Next-generation sequencing, Targeted resequencing",
author = "Chiara Reale and Celeste Panteghini and Miryam Carecchio and Barbara Garavaglia",
year = "2018",
month = "3",
day = "1",
doi = "10.1016/j.ejpn.2018.01.013",
language = "English",
volume = "22",
pages = "285--291",
journal = "European Journal of Paediatric Neurology",
issn = "1090-3798",
publisher = "W.B. Saunders Ltd",
number = "2",

}

TY - JOUR

T1 - The relevance of gene panels in movement disorders diagnosis

T2 - A lab perspective

AU - Reale, Chiara

AU - Panteghini, Celeste

AU - Carecchio, Miryam

AU - Garavaglia, Barbara

PY - 2018/3/1

Y1 - 2018/3/1

N2 - Next-Generation Sequencing (NGS) is a group of new methods that allow sequencing a variable number of known genes (targeted resequencing) or even the whole human genome (whole genome sequencing-WGS) and have contributed to an exponential genetic knowledge growth, especially in rare diseases, in the past few years. Since 2015, in the Molecular Neurogenetics Unit of Neurological Institute “Carlo Besta”, some gene panels have become available to screen all the known genes associated with Movement Disorders (MD) in children and adults as a diagnostic package. Over 221 patients analyzed (part of the Telethon Network of Genetic Biobanks – TNGB), pathogenic variants were found in 25 (11.31%), allowing a definitive genetic diagnosis. Among them, we found mutations in 10/114 patients with dystonia (8.8%); 10/59 patients with Parkinson's disease (16.9%); 1/25 patients with Neurodegeneration with Brain Iron Accumulation (NBIA) (4%) and 4/23 patients with neurotransmitter and biopterin metabolism synthesis defect (17.4%). Our results are in line with those published in literature; targeted resequencing does not replace Sanger sequencing totally, but its usage needs to be discussed with clinicians taking into account both the patient's clinical picture and radiological and neurophysiological data.

AB - Next-Generation Sequencing (NGS) is a group of new methods that allow sequencing a variable number of known genes (targeted resequencing) or even the whole human genome (whole genome sequencing-WGS) and have contributed to an exponential genetic knowledge growth, especially in rare diseases, in the past few years. Since 2015, in the Molecular Neurogenetics Unit of Neurological Institute “Carlo Besta”, some gene panels have become available to screen all the known genes associated with Movement Disorders (MD) in children and adults as a diagnostic package. Over 221 patients analyzed (part of the Telethon Network of Genetic Biobanks – TNGB), pathogenic variants were found in 25 (11.31%), allowing a definitive genetic diagnosis. Among them, we found mutations in 10/114 patients with dystonia (8.8%); 10/59 patients with Parkinson's disease (16.9%); 1/25 patients with Neurodegeneration with Brain Iron Accumulation (NBIA) (4%) and 4/23 patients with neurotransmitter and biopterin metabolism synthesis defect (17.4%). Our results are in line with those published in literature; targeted resequencing does not replace Sanger sequencing totally, but its usage needs to be discussed with clinicians taking into account both the patient's clinical picture and radiological and neurophysiological data.

KW - Gene panel

KW - Movement disorders

KW - Next-generation sequencing

KW - Targeted resequencing

UR - http://www.scopus.com/inward/record.url?scp=85041109390&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85041109390&partnerID=8YFLogxK

U2 - 10.1016/j.ejpn.2018.01.013

DO - 10.1016/j.ejpn.2018.01.013

M3 - Review article

VL - 22

SP - 285

EP - 291

JO - European Journal of Paediatric Neurology

JF - European Journal of Paediatric Neurology

SN - 1090-3798

IS - 2

ER -